Company intelligence / Profile preview

Nanose Medical

Ownership: Private
Development stage: Preclinical

Overview

Nanose Medical is currently conducting clinical studies in five hospitals, supported by EU grants and other funding. Their non-invasive handheld device uses nanotechnology sensor arrays and AI algorithms to analyze breath for early detection of diseases such as lung cancer and liver disease. The technology aims to improve patient stratification, reduce screen failure rates in clinical trials, and enable population-level screening with high portability and low cost[1][3][4].

Therapeutic areas: OncologyGastroenterology
Modalities: DeviceDigital health technologyNanoparticle (nanotechnology-based sensors)
Industry: Metabolite Diagnostics

Partnerships

LUCIA consortium under Horizon Europe Program for lung cancer researchTechnion Israel Institute of TechnologyHadassah Medical Center

Beyond the preview

Go deeper on Nanose Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nanose Medical.

Explore the full profile